Hill Publishing Group | contact@hillpublisher.com

Hill Publishing Group

Location:Home / Journals / International Journal of Clinical and Experimental Medicine Research /


Effect of Tacrolimus in Triple Negative Breast Cancer Animal Model

Date: May 28,2021 |Hits: 163 Download PDF How to cite this paper

Safiye Aktas1,*, Ayşe Pınar Ercetin1, Efsun Kolatan2

1Department of Basic Oncology, Dokuz Eylül University Institute of Oncology, Izmir, Turkey.

2Department of Laboratory of Animal Science, Dokuz Eylul University School of Medicine, Izmir, Turkey.

*Corresponding author: Safiye Aktas


Aim: Triple negative breast cancer has poor prognosis requiring new combination treatments strategies. Structurally resembling the best known mTOR inhibitor of rapamycin and a calcineurin inhibitor, tacrolimus modulates mTOR in the absence of rapamycin with antiproliferative efficacy shown for cancer types like glioblastoma multiforme, hepatocellular carcinoma, and lymphoma, the aim of this study is to assess the efficacy of tacrolimus on tumor cells from an in vitro 4T1 cell line representing triple-negative breast cancer and in a cancer model in experimental animals. Method: 4T1 triple-negative breast cancer cell line was incubated with tacrolimus (1, 10, 20, 30, 40, 50, 100 µm) for 24, 48 and 72 hours. Cell viability percentages were assessed with WST-1 analysis. 14 athymic nude mice with mean weight 25 g aged 5-7 weeks were injected with 4T1 cells subcutaneously. After 150 mm3 tumor development, animals were randomized into a control group administered physiologic serum and an experimental group administered 10 mg/kg tacrolimus, on the 1st and 8th days via the intraperitoneal route. On the 14th day, animals were sacrificed and changes in tumor tissue were examined histopathologically and for apoptosis with flow cytometry with annexin-V and propidium iodide in fresh tissue suspension. Results: The LD50 dose of tacrolimus was identified as 30 µM. In the triple-negative breast cancer model in experimental animals, the targeted tumor size was reached in 8-12 days. Side effects were not observed from the two doses of tacrolimus administered at a one-week interval. After sacrifice on the 14th day, histopathologic assessment of tumor tissues observed prominent necrosis, necrobiosis and apoptosis in the tumor group compared to the control group. Annexin-V+PI flow cytometry investigation found the early apoptotic effect of tacrolimus was higher compared to late apoptosis and necrosis. Conclusion: Tacrolimus was found to be effective both in vitro and in vivo on triple-negative breast cancer triggering necrosis in addition to apoptosis. Tacrolimus is promising as a treatment choice for the clinical problem of triple-negative breast cancer.


[1] Al-Hajj, M., Wicha, M. S., Benito-Hernandezt, A., Morrison, S. J., Clarke, M. F.  (2003). Prospective identification of tumorigenic breast cancer cells. PNAS, 100(7): 3983-88.

[2] Hassan, B. A., Yusoff, Z. (2011). Negative Impact of Chemotherapy on Breast Cancer Patients QOL—Utility of Antiemetic Treatment Guidelines and the Role of Race. Asian Pacific J Cancer Prev, 1523-1527.

[3] Russell, C. A. (2014). Personalized medicine for breast cancer: it is a new day! Am J Surg, 207: 321-5.

[4] Gaudet, M. M., Press, M. F., Haile, R. W., Lynch, C. F., Glaser, S. L., Schildkraut, J., Gammon, M. D., Douglas Thompson, W., Bernstein, J. L. (2011). Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or younger. Breast Cancer Res Treat., 130(2): 587-597.

[5] Marshall, J. C., Collins, J. W., Nakayama, J., Horak, C. E., Liewehir, H. J., Steinberg, S. M., Albaugh, M., Vidal-Vanaclocha, F., Palmieri, D., Barbier, M., Murone, M., Steeg, P. S. (2012). Effect of inhibition of the lysophosphatidic acid receptor 1 on metastasis and metastatic dormancy in breast cancer. J Natl Cancer Inst., 104(17): 1306-19. 

[6] Bernstein, L., Lacey, J. V. Jr. (2011). Receptors, associations and risk factor differences by breast cancer subtypes: positive or negative? J Natl Cancer Inst., 103: 451-453.

[7] Boyle, P. (2012). Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol, 23 Suppl 6: vi7-vi12.

[8] Hudis, C. A. (2011). Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist, 16: 1-11. 

[9] Yang, H., Rudge, D. G., Koos, J. D., Vaidialingam, B., Yang, H. J., Pavletich, N. P. (2013). mTOR kinase structure, mechanism and regulation. Nature, 497: 217-23.

[10] Shaw, R. J., Cantley, L. C. (2006). Ras, PI(3)K, and mTOR signalling controls tumor cell growth. Nature, 441: 424-30.

[11] Zaytseva, Y. Y., Valentino, J. D., Gulhati, P., Evers, B. M. (2012). mTOR inhibitors in cancer therapy. Cancer Letters, 319: 1-7.

[12] Yu, K., Toral-Barza, L. (2012). Biochemical and pharmacological inhibition of mTOR by rapamycin and an ATP-competitive mTOR inhibitor. Methods Mol Biol, 821: 15-28. 

[13] Maguire, O., Tornatore, K. M., O'Loughlin, K. L., Venuto, R. C., Minderman, H. (2013). Nuclear translocation of nuclear factor of activated T cells (NFAT) as a quantitative pharmacodynamic parameter for tacrolimus. Cytometry A, 83: 1096-104. 

[14] Augusto, J. F., Subra, J. F., Onno, C., Villemain, F., Croue, A., Dussaussoy, C., Picquet, J., Coeffic, B., Sayegh, J. (2013). Long-term maintenance immunosuppressive regimen with tacrolimus monotherapy. Ann Transplant, 18: 368-77. 

[15] Siamakpour-Reihani, S., Caster, J., Bandhu, Nepal, D., Courtwright, A., Hilliard, E., Usary, J., Ketelsen, D., Darr, D., Shen, X. J., Patterson, C., Klauber-Demore, N. (2011). The role of calcineurin/NFAT in SFRP2 induced angiogenesis--a rationale for breast cancer treatment with the calcineurin inhibitor tacrolimus. PLoS One, 2011, 6(6): e20412. 

[16] Jeong, I. J., Lee, S. G., Kim, Y. H., Ko, B. S., Lee, J. W., Son, B. H., Ahn, S. H., Kim, H. J. (2017). Characteristics and prognosis of breast cancer after liver or kidney transplantation. Breast Cancer Res Treat, https://doi.org/10.1007/s10549-017-4504-1.

[17] Sendur, M. A., Zengin, N., Aksoy, S., Altundag, K. (2014). Everolimus: a new hope for patients with breast cancer. Curr Med Res Opin., 30(1): 75-87.  

[18] Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., Litton, J. K., Chavez-MacGregor, M., Ibrahim, N. K., Murray, J. L. 3rd, Koenig, K. B., Hong, D., Subbiah, V., Kurzrock, R., Janku, F., Moulder, S. L. (2017). Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. JAMA Oncol., 3: 509-515.

How to cite this paper

Effect of Tacrolimus in Triple Negative Breast Cancer Animal Model

How to cite this paper: Safiye Aktas, Ayşe Pınar Ercetin, Efsun Kolatan. (2021) Effect of Tacrolimus in Triple Negative Breast Cancer Animal ModelInternational Journal of Clinical and Experimental Medicine Research5(3), 269-277.

DOI: http://dx.doi.org/10.26855/ijcemr.2021.07.007

Volumes & Issues

Free HPG Newsletters

Add your e-mail address to receive free newsletters from Hill Publishing Group.

Contact us

Hill Publishing Group

8825 53rd Ave

Elmhurst, NY 11373, USA

E-mail: contact@hillpublisher.com

Copyright © 2019 Hill Publishing Group Inc. All Rights Reserved.